Stomach Submucosal Tumors: A Comprehensive Guide
"From detection to treatment, understand the landscape of stomach submucosal tumors and their management."
Stomach submucosal tumors (SMTs) encompass a variety of lesions within the digestive tract. These lesions develop from different layers of the digestive tube, ranging from deep within the mucosa to the serosa, and may originate from tumors or other non-tumorous sources. While the term 'subepithelial lesions' might be more accurate, SMT remains the preferred term in common practice, especially in endoscopy.
Distinguishing these lesions is crucial because some carry a potential for malignancy. SMTs are detected in approximately one out of every 300 endoscopies, with about 60% located in the stomach. Gastric SMTs are often asymptomatic, covered by normal mucosa, and discovered incidentally during endoscopies or radiological examinations. In other instances, digestive bleeding is the most frequent symptom.
When a submucosal-appearing lesion is detected during endoscopy, the initial step involves differentiating it from external compression. Endoscopy alone has limited efficacy for this purpose (39-69%). Endoscopic ultrasound (EUS) is the key examination, superior to endoscopy, transabdominal ultrasound, or computed tomography. EUS demonstrates a sensitivity of 92% and specificity of 100% in differentiating between SMTs and external compression in a prospective study. The subsequent step consists of determining the nature of the SMT, if possible.
Epidemiology and Patient Impact
Gastrointestinal stromal tumors (GISTs) are rare but are the most common mesenchymal tumors of the digestive tract. Onkopedia reports that men and women are affected at approximately equal frequency, with a median age of onset of 65 to 70 years. Epidemiological assessment has historically been limited because diagnostic criteria were inconsistent and GIST lacked a specific ICD code, although SEER-22 and SEER-17 data have been used to study diagnoses from 2000 through 2019.
Diagnosis and Treatment Pathways
Endoscopic ultrasonography (EUS) is described as the most common method for evaluating gastrointestinal subepithelial lesions. However, EUS commonly requires histopathological confirmation obtained through invasive methods, which is a central limitation of the diagnostic pathway. For localized tumors, reported treatment options include endoscopic resection when feasible, laparoscopic resection, or open surgery; benign submucosal tumors are generally excised only when symptomatic, while GISTs require particular precautions.
From Mesenchymal Tumors to Molecular Classification
GISTs were recognized as rare gastrointestinal neoplasms that often present asymptomatically and can undergo malignant transformation. They are described as arising from the interstitial cells of Cajal, or similar cells, which are pacemaker cells associated with gastrointestinal smooth muscle. Subsequent molecular understanding emphasized the KIT gene and its receptor tyrosine kinase signaling pathway, while current prognostic assessment considers mitotic rate, tumor size, tumor location, surgical resection, and KIT mutation status.
Understanding the Nature and Origin of Stomach Tumors
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, developing at the expense of Cajal cells or one of their precursors. They reside in approximately 65% of cases in the stomach and 25% of cases in the small intestine. GISTs are now perfectly defined on the nosological level, in particular by the expression in immunohistochemistry of the KIT protein (95% of cases). An activating mutation of the KIT genes or more rarely PDGFRA is found in approximately 85% of cases. Their potential for malignancy is all the more important as their size and their mitotic index are high.
- Schwannomas are very rare digestive tumors of nervous origin, benign, whose digestive location most frequently is the proximal part of the stomach. Schwannomas express protein S-100 in immunohistochemistry, but neither KIT nor desmin.
- Lipoma is a benign tumor consisting of mature fat cells. It is rarer in the stomach than in the colon.
- Other gastric mesenchymal tumors are exceptional. There are a small number of GISTs that do not express KIT in immunohistochemistry (5%). It is therefore recommended, in these cases where the histology is evocative of GIST, to search for a mutation of the KIT or PDGFRA genes.
Molecularly Guided Advances
Recent research has identified FGF4 overexpression in some SDH-deficient and quadruple wild-type GISTs, arising through hypermethylation or other genomic alterations. A contemporary review describes genotype-directed therapy as an important focus of current work in molecular biology, pathology, risk stratification, and management. In advanced GIST, sequential tyrosine kinase inhibitor treatment uses imatinib as standard first-line therapy, followed by sunitinib, regorafenib, and ripretinib in resistant disease.
Limits of Current Evidence
Management of gastric submucosal tumors remains challenging because lesions may be difficult to classify before tissue confirmation. Diagnostic uncertainty can affect decisions about surveillance, resection, and the intensity of treatment. As a result, clinical decisions may need to balance the potential risks of invasive procedures against the possibility that an apparently indolent lesion represents a clinically important tumor.
Distinguishing Similar Lesions
GISTs and leiomyomas can both appear as smooth, submucosal gastric masses with normal overlying mucosa and bulging into the gastric lumen. Because GIST is the most common gastric submucosal tumor, other lesions may be mistaken for it, and standard endoscopic forceps biopsy often cannot provide an accurate diagnosis. Gastric schwannomas are another important differential diagnosis; the cited report states that complete surgical resection usually has a good prognosis with a low probability of recurrence.
The Importance of Ongoing Research
The incidental discovery of a gastric SMT during an endoscopy is quite frequent. Recent data has shown that GISTs are the most frequent tumorous lesion. EUS is the key examination for the study of gastric SMTs. It may allow in some cases to establish a presumptive diagnosis and guides the management modalities (monitoring, endoscopic or surgical resection, EUS-guided puncture). Prospective studies are needed to better understand the natural history of SMTs and to better define the role of EUS in the follow-up when a resection is not performed. This would allow to establish recommendations in the management of gastric SMTs that currently exist only for GISTs.
Integrating Diagnosis and Management
A comprehensive approach to submucosal tumors must connect diagnostic assessment with therapeutic indications. The cited review examined published PubMed literature from 1990 through March 2013 using the terms submucosal tumor and disease-specific names. This evidence base is intended to guide diagnostic measures and treatment decisions when a submucosal tumor has not yet received histological confirmation.
Follow-Up, Forecasting, and Precision Care
Future work includes evaluating the long-term course and growth speed of gastric submucosal tumors followed with EUS, particularly to assess the validity of guideline-based follow-up. A 2024 cohort study of 23,001 patients found that age-adjusted incidence rates for common digestive GISTs increased by 2% to 7% between 2000 and 2019, mostly for early-stage tumors, while also identifying survival disparities among some racial and ethnic groups. Molecular genetic and immunohistochemical testing is expected to remain important for subclassifying genomic subtypes and informing treatment decisions, alongside epidemiological forecasting through 2036 in the United States, EU4, the United Kingdom, and Japan.
Uneven Evidence and Access
The broader challenge is that submucosal tumors encompass lesions with different biological behaviors, diagnostic requirements, and treatment thresholds. Differences in classification, access to EUS or tissue diagnosis, and availability of molecular testing may complicate consistent care. These factors support individualized evaluation and careful interpretation of evidence rather than assuming that every gastric submucosal mass has the same risk.
Living With Diagnostic Uncertainty
For patients, the pathway from finding a gastric submucosal lesion to establishing its identity can involve surveillance, invasive sampling, or resection. Uncertainty about whether a lesion is benign, malignant, or simply difficult to classify can make treatment decisions especially consequential. Clear communication about diagnostic limits, follow-up, and the reasons for selecting observation or intervention is therefore an important part of patient-centered care.